Neoadjuvant immunotherapy is changing the treatment paradigm for patients with advanced cutaneous melanoma. This systemic approach leverages the presence of tumor antigens to generate a robust and durable antitumor immune response compared to traditional adjuvant therapy. The comprehensive review highlights contemporary clinical trials shaping the landscape of melanoma treatment algorithms. Single-modality agents and combination regimens are outlined along with response-adapted strategies, which aim to balance efficacy and toxicity. These novel neoadjuvant immunotherapy strategies promise to further refine treatment in a personalized manner, ideally offering patients the opportunity for greater response, reduced treatment toxicity, and improved long-term survival.
新辅助免疫疗法正在改变晚期皮肤黑色素瘤患者的治疗模式。与传统辅助治疗相比，这种系统性治疗方法利用肿瘤抗原的存在，能够产生更强大且持久的抗肿瘤免疫应答。本综述重点探讨了当前正在塑造黑色素瘤治疗格局的临床试验，概述了单药治疗方案与联合治疗方案，并介绍了旨在平衡疗效与毒性的应答适应性策略。这些创新的新辅助免疫治疗策略有望以个性化方式进一步完善治疗方案，为患者提供获得更好疗效、降低治疗毒性并改善长期生存的机会。
肿瘤(癌症)患者之家